Contractual penalty lawsuit, attachment orders, and criminal complaint costs
Some say payments to PR agency are delayed
Financial resources strained as dispute drags on

Shin Dong-kuk, chairman of Hanyang Precision and a key figure in the management-control dispute at Hanmi Pharmaceutical Group, is facing financial pressure from a series of legal battles and hefty interest payments on loans, according to reports. With annual interest payments on stock-backed loans nearing KRW 20 billion, a KRW 60 billion contractual penalty lawsuit, a KRW 10 billion attachment order, and criminal complaints all weighing on him, his costs are snowballing. Allegations that payments to his public relations agency have also been delayed are adding to concerns within and outside the group.


According to legal and industry sources on October 19, the legal disputes surrounding Shin have expanded to include civil lawsuits, provisional measures such as asset attachments, and criminal proceedings. Each case requires separate legal review and litigation responses. In addition, the disputes may drag on because they are intertwined with the management-control battle, leading legal costs to accumulate to a substantial level.


Management-control disputes involving large law firms can incur sharply higher advisory and legal fees depending on the number of lawyers assigned and the hours they work. Shin's legal representatives include Hwawoo, and Jung Jin-soo, managing partner of Hwawoo, is also reportedly involved directly. With civil and criminal cases overlapping with legal advice on management control, some observers expect cumulative legal costs could reach tens of billions of won. For Shin, who has taken on massive debt to secure management control, litigation costs are adding to his financial burden.

Legal costs alone could reach tens of billions of won... Can Shin Dong-kuk weather the management dispute? View original image

KRW 60 Billion Contractual Penalty Lawsuit and Criminal Complaint


The largest legal dispute is a KRW 60 billion lawsuit seeking contractual penalties. On October 1, the Seoul Central District Court dismissed claims related to the case filed by Hanmi Pharmaceutical Group Chairwoman Song Young-sook, Vice Chairwoman Lim Ju-hyun, and the Killington side. However, the legal battle is expected to continue, as an appeal appears likely.


A separate dispute over an attachment order related to a KRW 10 billion contractual penalty is also underway. Shin's side sought a contractual penalty from Vice Chairwoman Lim and applied for an attachment order against her Hanmi Science shares. In response, Lim's side also applied for a KRW 10 billion attachment order against shares held by Shin, which the court granted.


The specific grounds for granting the order were not disclosed, but industry observers are focused on the ongoing conflict over whether the four-party agreement was breached during Shin's efforts to increase his stake in Hanmi Science. With both sides seeking protective measures against the other's share assets, the management-control dispute is expanding into a legal battle over compliance with the four-party agreement and legal liability.

Hanmi Pharmaceutical's headquarters in Songpa-gu, Seoul. Yonhap News Agency.

Hanmi Pharmaceutical's headquarters in Songpa-gu, Seoul. Yonhap News Agency.

View original image

Criminal proceedings are also underway. Three former executives of Hanmi Pharmaceutical Group filed a criminal complaint against Shin over alleged embezzlement and breach of trust involving hundreds of billions of won, and Shin's side filed a counter-complaint accusing them of making false accusations. With criminal cases added to the civil lawsuits, Shin must now respond to multiple legal disputes simultaneously.


A lawyer advising on the management-control dispute said, "The more complex and prolonged a dispute becomes, the more costs can spiral out of control. Even for someone with substantial financial resources, legal fees reaching tens of billions of won can be a significant financial burden that is difficult to ignore."

Annual Interest of KRW 20 Billion; Borrowings Expected to Exceed KRW 500 Billion

Funds spent on managing public opinion are also emerging as a burden. In February, Shin held a press conference with his legal representatives at Grand Hyatt Seoul in Yongsan-gu, Seoul, to address the replacement of Rosuzet's ingredients and the controversy over allegedly shielding an executive accused of sexual harassment. In August, he formally hired a personal public relations agency and outsourced media communications work to it. He has thus begun a full-scale effort to shape public opinion, using a professional public relations firm in addition to handling litigation through his legal representatives.


Public relations fees vary depending on the scope of the contract, staffing, and the intensity of crisis management and media relations. Standard monthly retainers generally range from several million to tens of millions of won, but additional costs may apply when intensive public opinion management and messaging strategies are needed, as in a management-control dispute. Some industry sources say payments to Shin's public relations agency have not been made smoothly, fueling questions about whether he has sufficient financial resources to sustain a protracted management-control battle.


Based on disclosed loan balances and interest rates, annual interest on Shin's stock-backed loans secured by shares in Hanmi Science and Hanmi Pharmaceutical is close to KRW 20 billion, based on his existing borrowings. If he also borrows to fund additional share purchases, his annual interest burden could exceed KRW 20 billion. Including the cost of the additional purchases, his personal stock-backed loans are expected to exceed KRW 500 billion.



A financial investment industry official said, "If efforts to secure management control using massive borrowings fail, the heavy interest costs and repayment obligations at maturity will remain. If refinancing runs into difficulties or the value of collateral falls, he could face pressure to provide additional collateral or sell his holdings. The debt taken on to secure management control could therefore backfire, threatening both his control and his financial foundation."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing